Dr. William Hunter reports

CARDIOME ANNOUNCES RECENT INSIDER PURCHASES

Dr. William Hunter, president and chief executive officer of Cardiome Pharma Corp., and Justin Renz, chief financial officer, purchased an aggregate total of 210,000 common shares of Cardiome on both the Toronto Stock Exchange and the Nasdaq on March 26, 2018. Details of the transactions can be found on the System for Electronic Disclosure by Insiders (SEDI). The purchases were made for investment purposes.

About Cardiome Pharma Corp.

Cardiome Pharma is a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Cardiome develops, acquires and commercializes brands for the in-hospital, acute care market segment. The company's portfolio of approved and marketed brands includes: Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome; and Esmocard and Esmocard Lyo (esmolol hydrochloride), a short-acting beta blocker used to control rapid heart rate in a number of cardiovascular indications. Cardiome's pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.

We seek Safe Harbor.